How should I write my abstract? What are the fatal flaws in a manuscript? What does it mean if reviewers give me a rejection with major revisions? What are my chances afterward? How should I feel about my work if I receive an early rejection? How important is it to write a strong rebuttal letter to the reviewers?
These are types of questions that will be tackled by all four of the Editors of AASLD’s journals at a special session “How to Get Published in an AASLD Journal” at The Liver Meeting® on Monday, October 23 at 7:30 am.
“As editors we thought that this will help people have a better insight into the operations of the journals and help authors gauge their work and find the appropriate home within the AASLD journals,” said Gyongyi Szabo, MD, PhD, FAASLD, Editor of Hepatology Communications.
Dr. Szabo will be joined on the panel by David Cohen, MD, PhD, FAASLD, Editor of HEPATOLOGY, the flagship journal of AASLD, Paul Martin, MD, FAASLD, Editor of Liver Transplantation, and Nancy Reau, MD, FAASLD, incoming Editor of Clinical Liver Disease (CLD).
“The AASLD journals provide an important venue for academic discourse among the membership and broader hepatology community,” noted Dr. Cohen. “This session will provide an orientation to the broad range of options available for publishing.”
Dr. Szabo added that each editor will give a brief introduction to their journal and the types of manuscripts they look for and then the audience will be free to ask questions.
“We hope to help authors understand the distinguishing features between the various journals because there is varied characteristics and flavors to the various journals,” she said.
For example, Dr. Szabo said Hepatology Communications, which is the newest AASLD journal, offers a publishing opportunity for those whose papers may not have made the cut for HEPATOLOGY, but still contain excellent research of interest to the liver community.
“We certainly for look for novelty, but we accept papers that are trailblazers in a way. There might be a new idea or new finding, but no detailed mechanism or a lot of supporting evidence for it. We also are open to controversial areas,” said Dr. Szabo.
Similarly, Clinical Liver Disease has more of an educational focus, according to Dr. Reau.
“CLD offers an excellent opportunity for both education for junior faculty and trainees, but also as a focused venue to begin awareness around topics of relevance and importance. The Emerging Liver Scholar content is an example of this creative opportunity,” she said.
The editors also hope to impart that the opportunities in the journals go beyond publishing manuscripts. There are also opportunities for those interested in being reviewers, future Editorial Board members and future editors.
“We are happy to work with up and coming stars and talent to have their experience as reviewers. We can look into finding a senior mentor for reviewers,” said Dr. Szabo. “My journal is interested in the mechanisms of how can we involve more junior people in the review process either as editors or board members or as reviewers.”
Dr. Reau agreed, citing opportunities in her journal as well.
“CLD remains a journal in evolution. As much as we can offer opportunity, we also appreciate direction. This session is a wonderful dialog to recruit those that would like to be involved as well as to obtain feedback regarding the journal’s direction,” she said.